Halozyme Therapeutics stock is trading -21.53% below its average target price of $62.44 after marking a 7.2% during today's morning session. Analysts are giving the Mid-Cap Biotechnology company an average rating of buy and target prices ranging from $50.0 to $75.0 per share.
Halozyme Therapeutics has an elevated short interest of 10.9%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 7.75. Only 1.08% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders. 100.4% of Halozyme Therapeutics shares are held by institutional investors, which indicates a high level of confidence in the stock.
Institutions Invested in Halozyme Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Blackrock Inc. | 14% | 17,430,019 | $854,070,931 |
| 2024-09-30 | Vanguard Group Inc | 10% | 12,895,096 | $631,859,704 |
| 2024-09-30 | State Street Corporation | 5% | 6,633,688 | $325,050,712 |
| 2024-09-30 | Snyder Capital Management, LP | 3% | 4,063,367 | $199,104,983 |
| 2024-09-30 | Alliancebernstein L.P. | 3% | 3,408,341 | $167,008,709 |
| 2024-09-30 | Artisan Partners Limited Partnership | 2% | 3,133,412 | $153,537,188 |
| 2024-09-30 | Geode Capital Management, LLC | 2% | 3,060,131 | $149,946,419 |
| 2024-09-30 | Macquarie Group Limited | 2% | 3,010,825 | $147,530,425 |
| 2024-09-30 | JP Morgan Chase & Company | 2% | 2,864,857 | $140,377,993 |
| 2024-09-30 | Congress Asset Management Co | 2% | 2,433,579 | $119,245,371 |
For these reasons, we consider that the Halozyme Therapeutics is the subject of mixed market sentiment.
